Nice

News

NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decid

News

Solving the elective care conundrum through digital innovation

NICE's Office for Digital Health opens its doors

UK cost-effectiveness agency NICE has this week officially opened the Office for Digital Health, one of the pillars of its five-year strategy out to 2026.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

Views & Analysis

Deep Dive: Market Access

It’s fair to say this is the most interesting time ever for market access.

Views & Analysis

The next five years of NICE: Challenges, opportunities, and ...

If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and more ready to adapt – and COVID-19 has proved that it is more than capable of doing

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE's Office for Digital Health opens its doors

Patients in England get fast access to AZ's Tagrisso in earl...

Deep Dive: Market Access

The next five years of NICE: Challenges, opportunities, and ...

Enhertu cleared for NHS use via Cancer Drugs Fund

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Nice

Editor's Picks